Is Medicamen Biotec overvalued or undervalued?

As of 29 August 2025, Medicamen Biotec's valuation grade has moved from expensive to fair, indicating a more favorable assessment of its stock price relative to its intrinsic value. The company is currently fairly valued. Key ratios include a PE Ratio of 49.17, an EV to EBITDA of 33.02, and a ROE of 4.08%.
In comparison to its peers, Medicamen Biotec's PE Ratio is significantly higher than that of Cipla, which stands at 23.82, and Dr. Reddy's Labs, at 18.56, both of which are considered attractive. Despite the recent stock performance showing a decline of 32.51% year-to-date compared to a 2.14% increase in the Sensex, the current valuation suggests that Medicamen Biotec is now positioned more favorably within the market landscape.